Sequoia Genetics, a newly launched private limited company, is dedicated to accelerating drug discovery and development by leveraging genetic data. Headquartered at the Translation and Innovation Hub in White City Science Park, London, Sequoia Genetics brings together a multidisciplinary team of industry experts, including biologists, clinicians, epidemiologists, statisticians, data scientists and bioinformaticians. With a strong foundation in academia, clinical medicine, and drug development, the team’s expertise extends across a wide range of specialties.
The company’s core mission is to collaborate with academic institutions, investors, and pharma and biotech firms, utilizing cutting-edge genetic research to guide and optimize drug development and discovery efforts. Sequoia Genetics’ scientists have an impressive publication record, particularly in drug target Mendelian randomization, a methodology that helps identify genetic variants to predict drug efficacy and safety.
In partnership with leading academic institutions specializing in genetic data methodologies, Sequoia Genetics is poised to play a key role in unlocking the power of human genetics to generate valuable insights for developing novel therapies. This collaboration-driven approach positions the company at the forefront of innovation.